報價延遲最少15分鐘:2024/06/21 01:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.05 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-18.81/-2.71
|
|
企業價值
4.37M
|
| 資產負債 |
|
每股賬面淨值
4.17
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/21 01:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for largepatient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. |